Meta‐analysis of head‐to‐head clinical trials comparing incretin‐based glucose‐lowering medications and basal insulin – an update including recently developed GLP‐1 receptor agonists and the GIP/GLP‐1 receptor co‐agonist tirzepatide

Nauck MA, Mirna AEA, Quast DR
Diabetes Obes Metab. Pub. online 26 Jan 2023.

Pregnancy after bariatric surgery

Fisher SA, Stetson BT, Kominiarek MA
JAMA. Pub. online 10 Feb 2023.

Four-year visual outcomes in the protocol W randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy

Maturi RK, Glassman AR, Josic K, et al.
JAMA. 2023;329(5):376-385.

Integrated safety and efficacy analysis of dasiglucagon for treatment of severe hypoglycaemia in individuals with type 1 diabetes

Heller S, Battelino T, Bailey TS, et al.
Diabetes Obes Metab.Pub. online 24 Jan 2023.

Associations of disordered eating with the intestinal microbiota and short-chain fatty acids among young adults with type 1 diabetes

Igudesman D, Crandell J, Corbin KD, et al.
Nutr Metab Cardiovasc Dis. 2023;33(2):388-398.

LDL-cholesterol control in the primary prevention of cardiovascular diseases: An expert opinion for clinicians and health professionals

Poli A, Catapano AL,  Corsini A, et al.
Nutr Metab Cardiovasc Dis. 2023;33(2):245-257.

Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial

Feig DS, Sanchez JJ, Murphy KE, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00004-9.

Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels

D’Andrea E, Wexler DJ, Kim SC, et al.
JAMA Intern Med. Pub. online 6 Feb 2023.

Frias J, Chien J, Zhang Q, et al.
Lancet Diabetes Endocrinol. Pub. online 6 Feb 2023.

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Laffel LM, Danne T, Klingensmith GJ, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(22)00387-4.